Deprecated: Hook jetpack_pre_connection_prompt_helpers is deprecated since version jetpack-13.2.0 with no alternative available. in /home4/intern61/public_html/wp-includes/functions.php on line 6031
About | Pacific Wellspring

Pacific Wellspring

Dealing with Dysfunction not Disease

Pacific Wellspring

About

Share the Knowledge!

Business Philosophy:

Science First: Our Commitment to Clients

PW’s guiding philosophy, “Science First,” is demonstrated by an unwavering commitment to research-driven lab tests, synergistic formulations based on the latest scientific literature and outcome research, and meaningful quantities of therapeutic ingredients. These fundamental standards also serve to define our promise to HCPs and their patients. PW’s Research and Development team will not only search the world for the most exclusive and cutting edge raw materials but also invent proprietary formulas so that PW products are both unique and clinically effective as well as safe and organically based.

Health Brand Products Always in the Hands of Health Professionals

PW firmly believes that the HCP plays a key role in maximizing the therapeutic benefit to patients. Our products and service are offered exclusively to HCPs and their patients through referral. We provide HCPs professional brand of nutritional supplements along with a strong educational program and outstanding service.

Test, Don’t Guess!

In order to identify the causative determinants of a disease that must be addressed in clinical situations, an objective mechanism is required to explore those nutritional and toxicological factors that are contributing on a molecular basis to health outcomes. Accordingly, laboratory testing to evaluate biochemical, toxicological and nutritional status in individual patients is an absolute prerequisite in modern health care to adequately investigate and manage health problem.

1. A New Healthcare Paradigm

2.1 The Challenge

The current medical paradigm is mainly designed for acute illness, trauma, and end-stage disease. Mainstream medical education focuses on sickness rather than on health. It’s apparent that this acute care medicine has been unable to effectively address the epidemic of chronic diseases, including metabolic syndrome, cardiovascular complications, obesity, liver disease, cancer, etc. and its associated costs. Disease based acute care medicine is the WRONG model to address chronic illness, because it doesn’t address WHY people are sick, or the underlying mechanisms and biologic causes.

The global population is exploding, reaching 7 billion. Many people are not ill but are technically not well and have no options available to them to achieve real health that is more than the absence of disease. According to WHO, 70% of the world’s population is in sub-health status. A survey of 16 major cities in China also confirmed the overall “Sub-health” population is 70% and cities with the highest percentage of sub-health people are Beijing (75.31?) and Shanghai (73.49?).

Furthermore, the Taiwanese government reported in 2003 that the total mortality rate due to “Metabolic Syndrome-based diseases” reached 27%. China’s Dept. of Health announced in 2004 that the prevalence rate and mortality rate of metabolic syndrome-based diseases were 52% and 30%, respectively for people ages 15 to 64.

Prevention must be the global focus of health care or we will lose the war against chronic disease with devastating human and economic consequences. Preventive medicine aims to prevent onset of chronic disease from sub-health and to stop, or even reverse, the progression of chronic conditions. This growing trend in sub-health conditions escalated the need, more than ever, to establish a preventive medicine program. This offers us a unique opportunity to tap into the truly new “green” venture in Asia.

According to the CEO of J&J, a major US pharmaceutical company, the current market size of preventative medicine worldwide is US $1 trillion annually. The potential of chronic disease management is even greater.

2.2. PW’s Solution

A new paradigm addresses the fundamental, underlying causes of chronic diseases, and can form the basis for a more effective model of medical education, practice, and research. Over time this approach will generate dramatic cost savings and improved health outcomes. That model exists today, and is called Integrative Functional Medicine (IFM).This new paradigm is personalized, preventive, participatory, predictive, prospective, and patient centered. It is proactive rather than reactive. It based on systems biology, physiology or medicine for addressing the causes of disease and optimizing biologic function in the body’s core physiologic systems, not only treating the symptoms. Therefore, IFM is the best solution for today’s health care crisis in both developed countries and emerging markets.

The company goal of PW is to provide total service of IFM in Asia in the following areas:

  • Establish PW-ASIA for distributing a series of unique and patent protected IFM tests along with a comprehensive set of effective professional brand nutraceuticals to HCPs in each of the PW participating Asian countries.
  • Build Pacific-Metametrix Lab, the first centralized integrative functional medicine diagnostic laboratory in Asia with a JV partner, Metametrix. Metametrix is the pioneer of IFM and a global laboratory leader in the development of metabolic, toxicant, and nutritional testing.
  • Build PW-IFM Clinic, franchise clinics which provide clinical services and serve as training centers in each major Asian city. To build an Asia health villa/spa model that teaches people steps to make healthier comprehensive lifestyle changes to live a better quality life. To not only live longer, but also to live better.
  • Drive public awareness on the increased evidence-based benefits of IFM and to educate Health Care Practitioners (HCPs) in integrative functional medicine (IFM), preventive health, and dietary therapies via seminars and online classes. An Asian-Pacific Institute of Integrative Functional Medicine will be formed to facilitate the HCPs’ continuing education on IFM, working corporately to conduct clinical outcome research on IFM.

PW’s Value Proposition

Team and Organization

There are currently four partners in the organization, namely: Deborah Cherng, MS, Nehemiah Cherng, MPH, PhD, Shirley Tamura, MPH, RD, DrPH, and Stephen Phua, MD. The current organizational structure is lean in order to facilitate quick and effective decision-making. Nevertheless, PW possesses a broad and effective network in the US and Asia with a wide spectrum of institutes, enterprises and advisors in preventive medicine.

  • Nehemiah Cherng holds a PhD in Epidemiology & Biostatistics and a bachelor’s degree in pharmacy. He worked as manager of education and research at Presbyterian Hospital and as an Assistant Professor at Univ. of Oklahoma, Oklahoma City for 4 years. He has also worked in the pharmaceutical and nutraceutical industry, including Byers, Bristol-Myers Squibs and Pfizer for 23 years. Dr. Cherng’s experience covers co-development of protocols and co-publishing with clinicians, conducting drug trials and filing IND and NDA to the USFDA, R&D, finance, investment management and business development. His previous job was co-founder and COO of a US pharmaceuticals with a subsidiary in Taiwan, responsible for R&D and marketing of new nutraceutical ingredients and natural products for 10 years.
  • Deborah Cherng has a master’s degree in statistics and has worked as a biostatistician for over 16 years in designing, conducting and analysis of HIV/AIDS clinical trials at the Harvard School of Public Health. She has a broad network in biopharmaceuticals through her work and being co-organizer of international bioscience conventions.
  • Shirley Tamura is a career nutritionist, registered as a dietitian (RD) since 1990 with a master’s degree in public health and a doctorate in public health specializing in nutrition-epidemiology from the Harvard School of Public Health. Dr. Tamura is currently an adjunct assistant professor teaching courses in nutrition and applied biology at University of Maryland University College Asian Division in Tokyo, Japan. She has over 18 years of experience in epidemiologic research and health education, specifically in chronic disease prevention and health promotion, having worked in public health clinics, schools, hospitals and wellness programs. Her particular area of expertise is in Asian dietary practices.
  • Stephen Phua received his medical degree from the University of Singapore. He is CEO and Managing Director of Fides Wellspring, a healthcare consulting company specializing in entry strategy to Asia. He was the CEO of Agenix Limited, listed on the Australian Stock Exchange. Agenix’s lead candidates are its high technology blood clot-imaging agent and anti-hepatitis B virus drug, and has established a subsidiary in China. Previously, as President and General Manager of Asia Pacific, he was responsible for IMS Health (NYSE: RX; the world’s leading provider of information solutions to pharmas and healthcare industries) operations in 17 Asia Pacific countries. Dr. Phua was group general manager of Parkway Health Group, a public company listed on the Singapore Stock Exchange that owns 12 hospitals in Southeast Asia. Prior to that, he was VP of clinical services at Covance Asia Pacific, one of the largest contract research organizations in the world. From 1987 to 1999, He held various medical and business development positions with Wellcome Pharmaceuticals and Rhone-Poulenc Rorer in Asia. He also has served on the advisory board of the Bioinformatics Center in Singapore and the Business Angel Networks of Southeast Asia. Dr Phua recently completed a Masters of Science program in Human Nutrition from the University of Bridgeport summa cum laude. He co founded the International Academy of Nutritional and Metabolic Medicine with Prof David Brady, the Head of the Human Nutrition Institute at the University of Bridgeport, Connecticut. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, UK.

Scientific Advisory Board

  • Professor Yung-chi Cheng is Henry Bronson Professor of Pharmacology and Professor of Medicine at Yale University Medical School as well as Director of the Developmental Therapeutics Program of the Yale Comprehensive Cancer Center. He is a leader in cancer and viral pharmacology and has recently developed an interest in the use of traditional Chinese medicine in cancer: he has 5 clinical candidates in the area of nucleoside analogs for antiviral therapy; he is a scientific chairman and a member of several federal boards and committees; he serves as a consultant for many pharmaceutical firms; and he is on the editorial board of many journals. He is Academician of Academia Sinica in the Republic of China and holds the honorary Professor title at 5 prominent Chinese Medical Universities. Professor Cheng is also the co-chair for the Consortium for the Globalization of Chinese Medicine, the co-founder of PhytoCeutica in 1999 and it’s Head Scientific Advisor. He obtained his Ph.D. in Biochemical Pharmacology from Brown University and his postdoctoral training was completed at Yale University.
  • Prof. Ke-Ji Chen, MD is Academician of China Academy of Sciences (elected in 1991) and the Honorable President of Chinese Association of Integrative Medicine. He was graduated from Fujian Medical College, China in 1954. He joined the China Academy of Chinese Medical Sciences in 1955 and has been appointed as the chief research fellow since 2000. He was the first generation specialist of integrative medicine, receiving the First Class Award of Western Medicine Doctor on Leave to Learn TCM. In 1959, Prof. Chen had carried on advanced learning in cardiology at the Institute of Cardiovascular Diseases, Chinese Academy of Medical Sciences, and in 1964, promoted as the Professor of Medicine at Xiyuan Hospital and Institute of Gerontology, China Academy of Chinese Medical Sciences. He has been Deputy Director of Academic Division of Biology, Chinese Academy of Sciences in 1998. In 2003, He won the Top Prize of National Science and Technology Progress for the study on blood stasis and activating blood circulation and removing stasis. He will lead several domestic and multi-country research/trials on integrative & functional medicine in collaboration with PW.
  • Prof. Il-Moo Chang, PhD is a Chair Professor of College of Oriental Medicine, Kyung Hee University after his retirement from College of Pharmacy. Seoul National University, Korea and a member of expert panel for traditional medicine, W.H.O. He was the director of the Collaborating Center of W.H.O. Western Pacific Region on Traditional Medicine at the Natural Products Research Institute. He earned PhD from Department of Biophysical Sciences, University of Houston in 1972. He started his academic profession at the Natural Products Research Institute, Seoul National University from 1976. Since then, he has examined the pharmacological effectiveness of traditional Chinese herbal drugs. He has published more than 140 scientific papers, and a dozen of books. A famous one is the Treatise of Asian Herbal Medicines (9 volumes). He has contribute has been a contributing editor for several journals such as the Journal of Evidence-based Complementary and Integrated Medicine; Res. Comm. in Molecular Pathology and Pharmacology; Chinese J. Integrated Medicine. An excellent achievement in harmonizing traditional Chinese and Modern medicines is to create a database of TradiMed DB which plays a role of gate way for modern and western scientists to understand wisdom of traditional Chinese herbal therapy.
  • Prof. Ping-Chung Leung, MD is Professor of Orthopaedics & Traumatology, Faculty of Medicine; Director of Centre for Clinical Trials on Chinese Medicine; and Chairman of the Institute of Chinese Medicine (ICM), The Chinese University of Hong Kong. His research areas include Orthopaedics, Osteoporosis, Microsurgery, Health, Traditional Chinese Medicine and General Education. He is also the author of over 350 scientific manuscripts in journals and 17 books. He has also been appointed as editor of 5 International Journals since 1982. As the Chairman of ICM, he has put enormous efforts in modernizing traditional Chinese medicine by adoption of an Efficacy Driven Approach in Clinical Trials. 60 clinical trials research projects underway in the ICM. Dr Leung plans to use IFM testing to some of the trials.
  • Prof. Mary M. Waye, PhD is full professor and the founding director of the Croucher Laboratory for Human Genomics, Department of Biochemistry, Faculty of Medicine, Chinese University of Hong Kong. She obtained her Ph.D. in Medical Biophysics from University of Toronto in 1982. She started teaching at The Chinese University of Hong Kong since 1992 and research interests include genomic studies on developmental dyslexia and other complex diseases such as diabetes and liver cancer. She joined the International HapMap consortium and helped in building an open resource for the study of the human genome. She is also the Chairperson of the Hong Kong Society of Biochemistry and Molecular Biology. She plans to co-author with PW for applying several Hong Kong industrial grants.

Bringing new products into Asia will be a challenge. However, our team understands the local market, because team members have engaged in business in Asia for many years. Local contacts and networks are vital to our success: PW has already garnered support of key persons, many of whom are MD’s and food or pharmaceutical executives in China, Korea, Taiwan and Singapore. All are eager to incorporate IFM into current clinics and hospitals. PW has IT support and is capable of administering its continuing education programs in IFM for all participating health care providers through online programs.


Facebook Comments